Protalix BioTherapeutics (PLX) EPS (Weighted Average and Diluted) (2011 - 2026)
Protalix BioTherapeutics' quarterly EPS (Weighted Average and Diluted) came in at $0.22 in Q1 2026, up 540.0% year-on-year from $0.03 in Q1 2025, and up 414.29% quarter-over-quarter from -$0.07 in Q4 2025.
Protalix BioTherapeutics has reported EPS (Weighted Average and Diluted) for 14 years, with the latest figure at $0.22 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 540.0% year-over-year to $0.22; the trailing twelve-month figure through Mar 2026 stood at $0.18 (up 350.0% YoY), and the FY2025 full-year result was -$0.08, down 300.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $0.22, up from -$0.07 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.22 in Q1 2026, with the low at -$0.11 in Q2 2022.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.01, with a median of -$0.05 recorded in 2022.
- Year-over-year, EPS (Weighted Average and Diluted) sank 177.78% in 2025 and surged 540.0% in 2026.
- Tracing PLX's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.07 in 2022, then changed by 0.0% to -$0.07 in 2023, then jumped by 228.57% to $0.09 in 2024, then plunged by 177.78% to -$0.07 in 2025, then soared by 414.29% to $0.22 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.22 (Q1 2026), -$0.07 (Q4 2025), and $0.03 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.22 |
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | 0.03 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | 0.09 |
| Sep 30, 2024 | 0.03 |
| Jun 30, 2024 | -0.03 |
| Mar 31, 2024 | -0.06 |
| Dec 31, 2023 | -0.07 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | 0.21 |
| Mar 31, 2023 | -0.05 |
| Dec 31, 2022 | -0.07 |
| Sep 30, 2022 | -0.07 |
| Jun 30, 2022 | -0.11 |
| Mar 31, 2022 | -0.05 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -0.25 |
| Mar 31, 2021 | -0.14 |
| Dec 31, 2020 | 0.03 |
| Sep 30, 2020 | -0.14 |
| Dec 31, 2019 | 0.01 |
| Jun 30, 2018 | -0.06 |
| Jun 30, 2017 | -0.06 |
| Jun 30, 2016 | -0.11 |
| Jun 30, 2013 | -0.07 |
| Jun 30, 2012 | 0.10 |
| Jun 30, 2011 | -0.16 |